Log in

Relevant bibliographies by topics / HIV-1 infectivity

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'HIV-1 infectivity'

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV-1 infectivity.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HIV-1 infectivity"

1

Fox, Philip C., Andy Wolff, Chih-Ko Yeh, Jane C. Atkinson, and Bruce J. Baum. "Saliva inhibits HIV-1 infectivity." Journal of the American Dental Association 116, no. 6 (May 1988): 635–37. http://dx.doi.org/10.14219/jada.archive.1988.0002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Maeda, Yosuke, Keisuke Yusa, and Shinji Harada. "Enhanced infectivity of HIV-1 by X4 HIV-1 coinfection." Biochemical and Biophysical Research Communications 308, no. 4 (September 2003): 906–13. http://dx.doi.org/10.1016/s0006-291x(03)01498-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hood, Joshua L., Andrew P. Jallouk, Nancy Campbell, Lee Ratner, and Samuel A. Wickline. "Cytolytic nanoparticles attenuate HIV-1 infectivity." Antiviral Therapy 18, no. 1 (2012): 95–103. http://dx.doi.org/10.3851/imp2346.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jones, Jennifer, William Whitford, Frederic Wagner, and Olaf Kutsch. "Optimization of HIV-1 infectivity assays." BioTechniques 43, no. 5 (November 2007): 589–94. http://dx.doi.org/10.2144/000112624.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

HAMMAR, LENA, IVAN HIRSCH, ALCYONE MACHADO, JEAN MAREUIL, JEAN BAILLON, and JEAN-CLAUDE CHERMANN. "Lectin Effects on HIV-1 Infectivity." Annals of the New York Academy of Sciences 724, no. 1 Slow Infectio (May 1994): 166–69. http://dx.doi.org/10.1111/j.1749-6632.1994.tb38907.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Jianyong, and Chen Liang. "BST-2 Diminishes HIV-1 Infectivity." Journal of Virology 84, no. 23 (September 22, 2010): 12336–43. http://dx.doi.org/10.1128/jvi.01228-10.

Full text

Abstract:

ABSTRACT Bone marrow stromal cell antigen 2 (BST-2, also known as tetherin/CD317/HM1.24) inhibits the release of human immunodeficiency virus type 1 (HIV-1) and other enveloped viruses by tethering virus particles to the cell surface. In this study, we provide evidence not only that the yield of cell-free HIV-1 particles is significantly reduced by BST-2 but also that the infectivity of these progeny virions is severely impaired. The lowered virion infectivity is due to the accumulation of pr55 Gag precursor and the p40Gag intermediates as well as to the loss of a mature core in the majority of HIV-1 particles. These data suggest that, in addition to impeding the release of HIV-1 particles from host cells, BST-2 may also interfere with the activation of viral protease and, as a result, impairs viral Gag processing as well as maturation of HIV-1 particles.

APA, Harvard, Vancouver, ISO, and other styles

7

Konopka, K., B. R. Davis, C. E. Larsen, and N. Düzgünes. "Cardiolipin liposomes specifically inhibit HIV-1 infectivity." Antiviral Research 15 (April 1991): 68. http://dx.doi.org/10.1016/0166-3542(91)90131-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rapatski, Brandy L., Frederick Suppe, and James A. Yorke. "Reconciling Different Infectivity Estimates for HIV-1." JAIDS Journal of Acquired Immune Deficiency Syndromes 43, no. 3 (November 2006): 253–56. http://dx.doi.org/10.1097/01.qai.0000243095.19405.5c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Müller, Barbara, Maria Anders, Hisashi Akiyama, Sonja Welsch, Bärbel Glass, Krisztina Nikovics, Francois Clavel, Hanna-Mari Tervo, Oliver T. Keppler, and Hans-Georg Kräusslich. "HIV-1 Gag Processing Intermediates Trans-dominantly Interfere with HIV-1 Infectivity." Journal of Biological Chemistry 284, no. 43 (August 7, 2009): 29692–703. http://dx.doi.org/10.1074/jbc.m109.027144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Crombie, René, Roy L. Silverstein, Clarinda MacLow, S. Frieda A. Pearce, Ralph L. Nachman, and Jeffrey Laurence. "Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva." Journal of Experimental Medicine 187, no. 1 (January 5, 1998): 25–35. http://dx.doi.org/10.1084/jem.187.1.25.

Full text

Abstract:

Human and non–human primate salivas retard the infectivity of HIV-1 in vitro and in vivo. Because thrombospondin 1 (TSP1), a high molecular weight trimeric glycoprotein, is concentrated in saliva and can inhibit the infectivity of diverse pathogens in vitro, we sought to determine the role of TSP1 in suppression of HIV infectivity. Sequence analysis revealed a TSP1 recognition motif, previously defined for the CD36 gene family of cell adhesion receptors, in conserved regions flanking the disulfide-linked cysteine residues of the V3 loop of HIV envelope glycoprotein gp120, important for HIV binding to its high affinity cellular receptor CD4. Using solid-phase in vitro binding assays, we demonstrate direct binding of radiolabeled TSP1 to immobilized recombinant gp120. Based on peptide blocking experiments, the TSP1–gp120 interaction involves CSVTCG sequences in the type 1 properdin-like repeats of TSP1, the known binding site for CD36. TSP1 and fusion proteins derived from CD36-related TSP1-binding domains were able to compete with radiolabeled soluble CD4 binding to immobilized gp120. In parallel, purified TSP1 inhibited HIV-1 infection of peripheral blood mononuclear cells and transformed T and promonocytic cell lines. Levels of TSP1 required for both viral aggregation and direct blockade of HIV-1 infection were physiologic, and affinity depletion of salivary TSP1 abrogated >70% of the inhibitory effect of whole saliva on HIV infectivity. Characterization of TSP1–gp120 binding specificity suggests a mechanism for direct blockade of HIV infectivity that might be exploited to retard HIV transmission that occurs via mucosal routes.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "HIV-1 infectivity"

1

Walker, Polly Rose. "Evolution and infectivity of HIV-1 subtype C viruses." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442985.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Newman, Edmund Nicholas. "Genetic and functional analysis of APOBEC3G : a suppressor of HIV-1 infectivity." Thesis, King's College London (University of London), 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.428527.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Auclair, Jared R. "Probing the Structural Topology of HIV-1 Virion Infectivity Factor (VIF): A Dissertation." eScholarship@UMMS, 2012. http://escholarship.umassmed.edu/gsbs_diss/359.

Full text

Abstract:

Human Immunodeficiency Virus Type 1 (HIV-1), the virus that causes Acquired Immunodeficiency Syndrome (AIDS), attacks the immune system leaving patients susceptible to opportunistic infections that eventually cause death. Highly Active Antiretroviral Therapy, HAART, is the current drug strategy used to combat HIV. It is a combination therapy that includes HIV-1 Reverse Transcriptase and HIV-1 Protease inhibitors. Drug resistant strains arise that evade current HAART treatments; therefore novel drugs are needed. HIV-1 regulatory proteins such as Tat, Rev, Nef, Vpr, Vpu, and Vif are attractive new drug targets. Of particular interest is the HIV-1 Vif protein and its cellular binding partner APOBEC3G. In the absence of HIV-1 Vif, APOBEC3G, a cytidine deaminase, is able to mutate the viral cDNA and render the virus noninfectious. HIV-1 Vif binds to APOBEC3G and targets it for proteosomal degradation through an interaction with a Cullin-RING ligase complex. Blocking the HIV-1 Vif APOBEC3G interaction would allow APOBEC3G to perform its antiviral function. An attractive strategy to target the HIV-1 Vif APOBEC3G interaction would be a structure-based one. To apply structure-based drug design approaches to HIV-1 Vif and APOBEC3G, I attempted to collect high resolution structural data on HIV-1 Vif and APOBEC3G. My attempts were unsuccessful because the milligram quantities of soluble protein required were not obtained. Therefore, in Chapter III I used chemical cross-linking and mass spectrometry to probe the structural topology of HIV-1 Vif obtaining low resolution structural data. Chemical cross-linking formed HIV-1 Vif multimers including dimers, trimers, and tetramers. Analysis of the cross-linked monomer revealed that HIV-1 Vif’s N-terminal domain is a well-folded, compact, globular domain, where as the C-teriminal domain is predicted to be disordered. In addition, disorder prediction programs predicted the C-terminal domain of HIV-1 Vif to be disordered. Upon oligomerization the C-terminal domain undergoes a disorder-to-order transition that not only facilitates oligomerization but may facilitate other protein-protein interactions. In addition, HIV-1 Vif oligomerization bring Lys34 and Glu134 in close proximity to each other likely creating one molecular surface forming a “hot spot” of biological activity. In Chapter IV I confirmed my low resolution structural data via peptide competition experiments where I identified peptides that can be used as scaffolds for future drug design. HIV-1 Vif oligomerization is concentration dependent. The HIV-1 Vif peptides Vif(29-43) and Vif(125-139) were able to disrupt HIV-1 Vif oligomerization, which confirms the low resolution structural data. HIV-1 Vif peptides Vif(25-39) and Vif(29-43) reduced the amount of APOBEC3G immobilized on the Protein A beads, reduced the amount of HIV-1 Vif interacting with APOBEC3G, or degraded APOBEC3G itself. These peptides could be used as scaffolds to design novel drugs that disrupt the function of HIV-1 Vif and or APOBEC3G. Therefore, low resolution structural data and peptide competition experiments were successful in identifying structurally important domains in HIV-1 Vif. They also provided insight into a possible mechanism for HIV-1 Vif function where a disorder-to-order transition facilitates HIV-1 Vif’s ability to interact with a diverse set of macromolecules. These data advance our structural understanding of HIV-1 Vif and they will facilitate future highresolution studies and novel drug designs.

APA, Harvard, Vancouver, ISO, and other styles

4

Auclair, Jared R. "Probing the Structural Topology of HIV-1 Virion Infectivity Factor (VIF): A Dissertation." eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsbs_diss/359.

Full text

Abstract:

Human Immunodeficiency Virus Type 1 (HIV-1), the virus that causes Acquired Immunodeficiency Syndrome (AIDS), attacks the immune system leaving patients susceptible to opportunistic infections that eventually cause death. Highly Active Antiretroviral Therapy, HAART, is the current drug strategy used to combat HIV. It is a combination therapy that includes HIV-1 Reverse Transcriptase and HIV-1 Protease inhibitors. Drug resistant strains arise that evade current HAART treatments; therefore novel drugs are needed. HIV-1 regulatory proteins such as Tat, Rev, Nef, Vpr, Vpu, and Vif are attractive new drug targets. Of particular interest is the HIV-1 Vif protein and its cellular binding partner APOBEC3G. In the absence of HIV-1 Vif, APOBEC3G, a cytidine deaminase, is able to mutate the viral cDNA and render the virus noninfectious. HIV-1 Vif binds to APOBEC3G and targets it for proteosomal degradation through an interaction with a Cullin-RING ligase complex. Blocking the HIV-1 Vif APOBEC3G interaction would allow APOBEC3G to perform its antiviral function. An attractive strategy to target the HIV-1 Vif APOBEC3G interaction would be a structure-based one. To apply structure-based drug design approaches to HIV-1 Vif and APOBEC3G, I attempted to collect high resolution structural data on HIV-1 Vif and APOBEC3G. My attempts were unsuccessful because the milligram quantities of soluble protein required were not obtained. Therefore, in Chapter III I used chemical cross-linking and mass spectrometry to probe the structural topology of HIV-1 Vif obtaining low resolution structural data. Chemical cross-linking formed HIV-1 Vif multimers including dimers, trimers, and tetramers. Analysis of the cross-linked monomer revealed that HIV-1 Vif’s N-terminal domain is a well-folded, compact, globular domain, where as the C-teriminal domain is predicted to be disordered. In addition, disorder prediction programs predicted the C-terminal domain of HIV-1 Vif to be disordered. Upon oligomerization the C-terminal domain undergoes a disorder-to-order transition that not only facilitates oligomerization but may facilitate other protein-protein interactions. In addition, HIV-1 Vif oligomerization bring Lys34 and Glu134 in close proximity to each other likely creating one molecular surface forming a “hot spot” of biological activity. In Chapter IV I confirmed my low resolution structural data via peptide competition experiments where I identified peptides that can be used as scaffolds for future drug design. HIV-1 Vif oligomerization is concentration dependent. The HIV-1 Vif peptides Vif(29-43) and Vif(125-139) were able to disrupt HIV-1 Vif oligomerization, which confirms the low resolution structural data. HIV-1 Vif peptides Vif(25-39) and Vif(29-43) reduced the amount of APOBEC3G immobilized on the Protein A beads, reduced the amount of HIV-1 Vif interacting with APOBEC3G, or degraded APOBEC3G itself. These peptides could be used as scaffolds to design novel drugs that disrupt the function of HIV-1 Vif and or APOBEC3G. Therefore, low resolution structural data and peptide competition experiments were successful in identifying structurally important domains in HIV-1 Vif. They also provided insight into a possible mechanism for HIV-1 Vif function where a disorder-to-order transition facilitates HIV-1 Vif’s ability to interact with a diverse set of macromolecules. These data advance our structural understanding of HIV-1 Vif and they will facilitate future highresolution studies and novel drug designs.

APA, Harvard, Vancouver, ISO, and other styles

5

Tanaka, Masakazu. "Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1." Kyoto University, 2003. http://hdl.handle.net/2433/148745.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rosa, Annachiara. "The cellular and molecular basis of the Nef requirement for HIV-1 infectivity." Doctoral thesis, Università degli studi di Trento, 2016. https://hdl.handle.net/11572/369203.

Full text

Abstract:

Nef is an HIV -1 accessory protein with a fundamental role for virus replication in vivo and for the development of AIDS. Among its several activities, Nef is essential for full HIV-1 infectivity, a function highly prominent in lymphoid cells. So far, the mechanism by which Nef promotes HIV-1 infectivity has remained elusive. Over the course of 3 years, my PhD research activity has led to the identification of the host transmembrane protein SERINC5, and to a lesser extent SERINC3, as potent inhibitors of HIV-1 infectivity counteracted by the viral protein Nef [Rosa et al., 2015]. SERINC5 is predominantly localized on the plasma membrane where it is efficiently incorporated into budding HIV-1 virions and impairs subsequent virion penetration of susceptible target cells. Nef relocalizes SERINC5 to an endosomal compartment preventing its incorporation into HIV-1 particles. The ability to counteract SERINC5 is conserved in Nef proteins encoded by different primate immunodeficiency viruses, as well as in the structurally unrelated glycosylated Gag from murine leukaemia virus (MLV). These examples of functional conservation and convergent evolution emphasize the fundamental importance of SERINC5 in the interaction of the host with retroviral pathogens. Remarkably, SERINC5 potently inhibits HIV-1 even in the presence of Nef in a dose-dependent manner, suggesting that this cellular factor might be exploited as an anti-HIV-1 therapeutic gene.

APA, Harvard, Vancouver, ISO, and other styles

7

Krapp, Christian [Verfasser]. "Guanylate binding protein 5 is an interferon-inducible inhibitor of HIV-1 infectivity / Christian Krapp." Ulm : Universität Ulm. Medizinische Fakultät, 2016. http://d-nb.info/1084767775/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Meyer, Bahiah. "The role of HIV-1 subtype B Envelope transmission motifs in subtype C variant infectivity." Master's thesis, University of Cape Town, 2018. http://hdl.handle.net/11427/29420.

Full text

Abstract:

Transmitted founders (TF) might carry motifs that provide a phenotypic advantage that enables human immunodeficiency virus type-1 (HIV-1) to overcome immune barriers within the female genital tract. One study compared over 5000 subtype B TF and mismatched chronic infection envelope (env) sequences and identified two putative transmission motifs: Histidine at position 12 of the signal peptide (His12) and a potential N-glycan site (PNG) at position 413-415. Although, His12 was shown to be important for subtype B Env expression and viral infectivity, in our own sequence analysis subtype C variants did not carry the transmission motifs and the aim of this study was to determine whether His12 and PNG413 was important for subtype C Env expression, processing, function and viral replication. Mutagenesis of a subtype C Env clone indicated that His12 decreased pseudovirion (PSV) entry efficiency without influencing Env expression, secretion and cleavage with no changes in the N-glycosylation profile. This suggested that His12 had a fitness cost and was thus selected against. However, His12 significantly enhanced the entry efficiency of infectious molecular clones (IMCs), suggesting that it might be beneficial for in vivo replication. The variation between the PSV and IMC entry of TZM-bl cells could be due to differences in assay conditions. On the other hand deletion of PNG413 enhanced Env expression, secretion, cleavage and PSV and IMC entry efficiency of TZM-bl cells. This would suggest that subtype C TFs carrying a PNG at 413-413 would have lower viral replicative capacity due to poor expression and processing of Env. The benefit of this phenotype on HIV-1 subtype C transmission needs to be further investigated. Unfortunately, PSV and IMC entry of TZM-bl cells could not be confirmed by IMC replication in peripheral blood monocytes because the clones could not replicate to measurable levels in these cells over the culture period. Overall, this study has shown that amino acid residues at positions 12 and 415 do play a role in modulating Env processing and function however the actual mechanism by which these polymorphisms impact viral fitness most likely differ to that of subtype B, explaining why His12 is absent and PNG413 is present in subtype C TFs.

APA, Harvard, Vancouver, ISO, and other styles

9

Camaur, Diana M. "Roles of virion associated proteins in HIV-1 infectivity : Vif, Nef and the matrix tyrosine kinase /." Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 1997. http://wwwlib.umi.com/cr/ucsd/fullcit?p9814538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Clemens, Rebecca [Verfasser]. "Characterization of a lipoprotein CD1348 from Clostridium difficile and the viral infectivity factor of HIV-1 / Rebecca Clemens." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2018. http://d-nb.info/1163804703/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "HIV-1 infectivity"

1

Düzgüneş, Nejat, Charles E. Larsen, Krystyna Konopka, Dennis R. Alford, Lawrence J. T. Young, Thomas P. McGraw, Brian R. Davis, Shlomo Nir, and Myra Jennings. "Fusion of HIV-1 and SIVmac with Liposomes and Modulation of HIV-1 Infectivity." In Mechanisms and Specificity of HIV Entry into Host Cells, 167–92. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5976-0_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

DeCamp, Dianne L., Lilia M. Babé, Paul Furth, Paul Ortiz de Montellano, Irwin D. Kuntz, and Charles S. Craik. "Structure-Based Inhibition of HIV-1 Protease Activity and Viral Infectivity." In Advances in Experimental Medicine and Biology, 489–92. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-6012-4_62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Johnson, Victoria A., Roy E. Byington, and Peter L. Nara. "Quantitative Assays for Virus Infectivity." In Techniques in HIV Research, 71–86. London: Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11888-5_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Di Bello, Carlo, Monica Dettin, Silvia Tormene, and Rossella Roncon. "The structure of synthetic peptides from the principal neutralizing domain of HIV-1 gp120 affects binding to CD4 and viral infectivity." In Peptide Chemistry 1992, 437–38. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1474-5_129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Di Bello, Carlo, Monica Dettin, Silvia Tormene, Rossella Roncon, Andrea Bagno, and Silvio Bicciato. "Conformational studies on synthetic peptides from the principal neutralizing domain of HIV-1 Gp120 that bind to CD4 and enhance viral infectivity." In Peptides, 95–97. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-010-9066-7_27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hadeler, K. P. "Structured Population Models for HIV Infection Pair Formation and Non-constant Infectivity." In AIDS Epidemiology, 156–73. Boston, MA: Birkhäuser Boston, 1992. http://dx.doi.org/10.1007/978-1-4757-1229-2_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Beck, Zoltan, and Carl R. "Interactions of Infectious HIV-1 Virions with Erythrocytes: Implications for HIV-1 Pathogenesis and Infectivity." In HIV-Host Interactions. InTech, 2011. http://dx.doi.org/10.5772/24074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Caroline, Subra, Burelout Chantal, Proulx Sophie, Simard Sebastien, and Gilbert Caroline. "Exosomes Decrease In Vitro Infectivity of HIV-1 Preparations: Implication for CD4+T Lymphocyte Depletion In Vivo." In Understanding HIV/AIDS Management and Care - Pandemic Approaches in the 21st Century. InTech, 2011. http://dx.doi.org/10.5772/19846.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Taber, Douglass F. "The Boger Synthesis of (+)-Complestatin." In Organic Synthesis. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780199965724.003.0102.

Full text

Abstract:

(+)-Complestatin 3 shows promising activity against HIV infectivity. Dale L. Boger of Scripps/La Jolla described (J. Am. Chem. Soc. 2010, 132, 7776) an elegant multicomponent assembly of 3, the key step of which was the atropisomer-selective intramolecular Larock cyclization of 1 to 2. The preparation of 1 began with the protected phenethylamine 5, prepared by Sharpless asymmetric aminohydroxylation of the styrene 4. Conversion of 5 to the areneboronic acid followed by coupling with 6 delivered 7. Acylation led to 8, with the stage set for nitro-assisted addition-elimination, to form the first bis-aryl ether of 3. The product was a mixture of atropisomers, subsequently symmetrized to 9 by removal of the nitro group. Acylation of 9 led to 1. The role of the silyl group on the alkyne of 1 was to direct the regioselectivity of the intramolecular Larock indole synthesis. Again, two atropisomers were possible from the cyclization. Earlier model studies had suggested some preference for one over the other. As it turned out, in this case the desired atropisomer was the only one observed. It is particularly striking that the coupling was efficient even in the presence of the readily reduced and unprotected chlorophenols. The modular nature of this route to (+)-complestatin 3 will make it possible to prepare a variety of analogues. As long as only the substituents on the periphery are changed, the atropisomer selectivity in the Larock cyclization should be maintained.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HIV-1 infectivity"

1

Ke, Hengming, Yingdong Zhao, Yongquan Chen, Mike Schutkowski, and Günter Fischer. "Is the cis-trans isomerization of cyclophilin involved in HIV-1 infectivity?" In Future Aspect in Peptide Chemistry - Ringberg Conference. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 1999. http://dx.doi.org/10.1135/css199901187.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!